vitiligo. vitiligo
Conditions
Interventions
Intervention 1: group 1:
capsule minocycline 100 mg daily for 3 months. Intervention 2: Group 2: NBUVB twice per week with 311 nm Wavelength, irradiance 1800–2000 µ W/cm 2 for 3 months.
Treatment - Drugs
Treatment - Other
group 1:
capsule minocycline 100 mg daily for 3 months
Group 2: NBUVB twice per week with 311 nm Wavelength, irradiance 1800–2000 µ W/cm 2 for 3 months
Sponsors
Isfahan Medical University
Eligibility
Sex/Gender
All
Age
8 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criterion: unstable Vitiligo with 20- 50% body surface area involvement. Exclusion criteria: age = 8 years or =50 years old; pregnancy or intention to become pregnant; breastfeeding; other severe systemic diseases e.g. cardiovascular, renal and hepatic failure; segmental vitiligo; acral vitiligo taking any other vitiligo treatment; history of having taken any medication that could interact with minocycline within the previous 3 months; history of photo-mediated disorders such as systemic lupus erythematous and xeroderma pigmentosa (XP) etc; known hypersensitivity to the study medication.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vitiligo stability. Timepoint: 0, 1st, 2nd, 3rd months. Method of measurement: Vitiligo disease activity score (VIDA). | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects of drug. Timepoint: End of first, second and third month of treatment. Method of measurement: Examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Naser Zeinali
Isfahanl University of Medical Sciences
Outcome results
None listed